MiMedx is in trouble, again; Pfizer's Avastin biosimilar wins FDA approval
→ The controversial MiMedx has dug itself a deeper hole. Senior officials at the wound care company, which has long been criticized for its business practices, are aware of at least fifty instances of patient complications associated with the use of MiMedx’s skin grafts or injections, Bloomberg reported on Thursday, citing sources and documents. The Marietta, Georgia-based company, counts veterans and military hospitals as its customers and is still reeling from a 15-month long sweeping internal investigation that painted a sordid picture of MiMedx’s scandalous past, indicating the company’s former C-suite spied on employees, lied to regulators and misled investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.